StockNews.com upgraded shares of Invitae (NYSE:NVTA – Free Report) from a sell rating to a hold rating in a report published on Wednesday morning. Several other equities research analysts have also commented on NVTA. Piper Sandler reduced their price objective on Invitae to $1.50 and set an underweight rating for the company in a research […]
StockNews.com upgraded shares of Invitae (NYSE:NVTA – Free Report) from a sell rating to a hold rating in a research note published on Wednesday. Other analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of Invitae to $1.50 and set an underweight rating on the stock […]
StockNews.com lowered shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a research note released on Tuesday morning. A number of other equities research analysts have also weighed in on NVTA. Raymond James lowered shares of Invitae from a market perform rating to an underperform rating in a […]
StockNews.com downgraded shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Thursday morning. Other research analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their price objective on Invitae from $1.50 to $1.00 and set a […]
Invitae Co. (NYSE:NVTA – Free Report) – Equities researchers at William Blair raised their Q3 2023 earnings per share (EPS) estimates for Invitae in a report issued on Wednesday, August 16th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of ($0.31) per share for the quarter, up from […]